Targeting adenosine for cancer immunotherapy
Sign Up to like & getrecommendations! Published in 2018 at "Journal for Immunotherapy of Cancer"
DOI: 10.1186/s40425-018-0360-8
Abstract: Immune checkpoint antagonists (CTLA-4 and PD-1/PD-L1) and CAR T-cell therapies generate unparalleled durable responses in several cancers and have firmly established immunotherapy as a new pillar of cancer therapy. To extend the impact of immunotherapy… read more here.
Keywords: immunotherapy; adenosine signaling; adenosine cancer; cancer immunotherapy ... See more keywords